{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:27:48Z","timestamp":1793878068903,"version":"4.7.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04494-3","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:44:58Z","timestamp":1767617098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5707-146X","authenticated-orcid":false,"given":"Bethany","family":"Joy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Ramsamooj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldo","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"4494_CR1","unstructured":"G.S. Alex Montero, & 2024, M. (2024, May 10). KFF Health Tracking Poll May 2024: The public\u2019s use and views of GLP-1 Drugs. KFF. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/"},{"key":"4494_CR2","unstructured":"J. Watanabe, (n.d.). Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. Journal of the American Pharmacists Association: JAPhA. https:\/\/pubmed.ncbi.nlm.nih.gov\/37821008\/"},{"key":"4494_CR3","unstructured":"L. Collins, (2024, February 29). Glucagon-like peptide-1 receptor agonists. StatPearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"issue":"10","key":"4494_CR4","doi-asserted-by":"publisher","first-page":"100736","DOI":"10.1016\/j.gastha.2025.100736","volume":"4","author":"S Garg","year":"2025","unstructured":"S. Garg, T. Qapaja, O. Hamid et al., All-cause mortality and Gastrointestinal adverse effects in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors. Gastro Hep Adv. 4(10), 100736 (2025). https:\/\/doi.org\/10.1016\/j.gastha.2025.100736","journal-title":"Gastro Hep Adv."},{"key":"4494_CR5","doi-asserted-by":"publisher","first-page":"204201882199732","DOI":"10.1177\/2042018821997320","volume":"12","author":"JM Trujillo","year":"2021","unstructured":"J.M. Trujillo, W. Nuffer, B.A. Smith, GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 12, 2042018821997320 (2021). https:\/\/doi.org\/10.1177\/2042018821997320","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"4494_CR6","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Z. Zhang, Q. Zhang, Y. Tan et al., GLP-1RAs caused Gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front. Endocrinol. (Lausanne). 14, 1149328 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1149328","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4494_CR7","doi-asserted-by":"publisher","unstructured":"A.J. Ahmann, M. Capehorn, G. Charpentier, F. Dotta, E. Henkel, I. Lingvay, A.G. Holst, M.P. Annett, V.R. Aroda, Efficacy and safety of Once-Weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-Week, Open-Label, randomized clinical trial, 41:258\u2013266, 2018. https:\/\/doi.org\/10.2337\/dc17-0417","DOI":"10.2337\/dc17-0417"},{"issue":"3","key":"4494_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"N. Alkhouri, R. Herring, H. Kabler, Z. Kayali, T. Hassanein, A. Kohli, R.S. Huss et al., Safety and efficacy of combination therapy with Semaglutide, Cilofexor and firsocostat in patients with Non-Alcoholic steatohepatitis: A Randomised, Open-Label phase II trial. J. Hepatol. 77(3), 607\u2013618 (2022). https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003","journal-title":"J. Hepatol."},{"issue":"2","key":"4494_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"KC Allison","year":"2023","unstructured":"K.C. Allison, A.M. Chao, M.B. Bruzas, C. McCuen-Wurst, E. Jones, C. McAllister, K. Gruber, R.I. Berkowitz, T.A. Wadden, J.S. Tronieri, A pilot randomized controlled trial of liraglutide 3.0 Mg for binge eating disorder. Obes. Sci. Pract. 9(2), 127\u2013136 (2023). https:\/\/doi.org\/10.1002\/osp4.619","journal-title":"Obes. Sci. Pract."},{"issue":"10019","key":"4494_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"M.J. Armstrong, P. Gaunt, G.P. Aithal, D. Barton, D. Hull, R. Parker, J.M. Hazlehurst et al., Liraglutide safety and efficacy in patients with Non-Alcoholic steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled phase 2 study. Lancet. 387(10019), 679\u2013690 (2016). https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"9","key":"4494_CR11","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"V.R. Aroda, J. Rosenstock, Y. Terauchi, Y. Altuntas, N.M. Lalic, E.C.M. Villegas, O.K. Jeppesen, E. Christiansen, C.L. Hertz, M. Haluz\u00edk, PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 42(9), 1724\u20131732 (2019). https:\/\/doi.org\/10.2337\/dc19-0749","journal-title":"Diabetes Care"},{"issue":"1","key":"4494_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"L.J. Aronne, N. Sattar, D.B. Horn, H.E. Bays, S. Wharton, W.-Y. Lin, N.N. Ahmad et al., Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331(1), 38\u201348 (2024). https:\/\/doi.org\/10.1001\/jama.2023.24945","journal-title":"JAMA"},{"issue":"6","key":"4494_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"A. Astrup, R. Carraro, N. Finer, A. Harper, M. Kunesova, M.E.J. Lean, L. Niskanen et al., Safety, tolerability and sustained weight loss over 2 years with the Once-Daily human GLP-1 Analog, liraglutide. Int. J. Obes. 36(6), 843\u2013854 (2012). https:\/\/doi.org\/10.1038\/ijo.2011.158","journal-title":"Int. J. Obes."},{"issue":"10103","key":"4494_CR14","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"D. Athauda, K. Maclagan, S.S. Skene, M. Bajwa-Joseph, D. Letchford, K. Chowdhury, S. Hibbert et al., Exenatide once weekly versus placebo in parkinson\u2019s disease: A Randomised, Double-Blind, placebo-Controlled trial. Lancet. 390(10103), 1664\u20131675 (2017). https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"issue":"8","key":"4494_CR15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"A. Blackman, G.D. Foster, G. Zammit, R. Rosenberg, L. Aronne, T. Wadden, B. Claudius, C.B. Jensen, E. Mignot, Effect of liraglutide 3.0 Mg in individuals with obesity and moderate or severe obstructive sleep apnea: the scale sleep apnea randomized clinical trial. Int. J. Obes. 40(8), 1310\u20131319 (2016). https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int. J. Obes."},{"issue":"6","key":"4494_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2337\/dc09-1914","volume":"33","author":"JB Buse","year":"2010","unstructured":"J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, H. Hu, K. Wilhelm, M. Trautmann, L.Z. Shen, L.E. Porter, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 33(6), 1255\u20131261 (2010). https:\/\/doi.org\/10.2337\/dc09-1914","journal-title":"Diabetes Care"},{"issue":"9861","key":"4494_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"J.B. Buse, M. Nauck, T. Forst, W.H.-H. Sheu, S.K. Shenouda, C.R. Heilmann, B.J. Hoogwerf et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A Randomised, Open-Label study. Lancet. 381(9861), 117\u2013124 (2013). https:\/\/doi.org\/10.1016\/S0140-6736(12)61267-7","journal-title":"Lancet"},{"issue":"9683","key":"4494_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label trial (LEAD-6). Lancet. 374(9683), 39\u201347 (2009). https:\/\/doi.org\/10.1016\/S0140-6736(09)60659-0","journal-title":"Lancet"},{"issue":"9","key":"4494_CR19","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/dom.13340","volume":"20","author":"YH Chen","year":"2018","unstructured":"Y.H. Chen, C.-N. Huang, Y.M. Cho, P. Li, L. Gu, F. Wang, J. Yang, W.Q. Wang, Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a Multicentre, Double-Blind, Randomized, Parallel-Arm, active Comparator, phase III trial. Diabetes Obes. Metabolism. 20(9), 2121\u20132130 (2018). https:\/\/doi.org\/10.1111\/dom.13340","journal-title":"Diabetes Obes. Metabolism"},{"issue":"10278","key":"4494_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"M. Davies, L. F\u00e6rch, O.K. Jeppesen, A. Pakseresht, S.D. Pedersen, L. Perreault, J. Rosenstock et al., Semaglutide 2\u00b74 Mg once a week in adults with overweight or Obesity, and type 2 diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, phase 3 trial. Lancet. 397(10278), 971\u2013984 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"issue":"5","key":"4494_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc12-1333","volume":"36","author":"M Davies","year":"2013","unstructured":"M. Davies, S. Heller, S. Sreenan, H. Sapin, O. Adetunji, A. Tahbaz, J. Vora, Once-Weekly exenatide versus Once- or Twice-Daily insulin Detemir. Diabetes Care. 36(5), 1368\u20131376 (2013). https:\/\/doi.org\/10.2337\/dc12-1333","journal-title":"Diabetes Care"},{"issue":"15","key":"4494_CR22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"M. Davies, T.R. Pieber, M.-L. Hartoft-Nielsen, O.K.H. Hansen, S. Jabbour, J. Rosenstock, Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial. JAMA - J. Am. Med. Association. 318(15), 1460\u20131470 (2017). https:\/\/doi.org\/10.1001\/jama.2017.14752","journal-title":"JAMA - J. Am. Med. Association"},{"issue":"7","key":"4494_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"M.J. Davies, R. Bergenstal, B. Bode, R.F. Kushner, A. Lewin, T.V. Skj\u00f8th, A.H. Andreasen, C.B. Jensen, R.A. DeFronzo, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7), 687\u2013699 (2015). https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"issue":"12","key":"4494_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1463-1326.2009.01154.x","volume":"11","author":"MJ Davies","year":"2009","unstructured":"M.J. Davies, R. Donnelly, A.H. Barnett, S. Jones, C. Nicolay, A. Kilcoyne, Exenatide compared with Long-Acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes. Metabolism. 11(12), 1153\u20131162 (2009). https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01154.x","journal-title":"Diabetes Obes. Metabolism"},{"issue":"9645","key":"4494_CR25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, D. Zhuang, L. Porter, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A Randomised, Open-Label, Non-Inferiority study. Lancet. 372(9645), 1240\u20131250 (2008). https:\/\/doi.org\/10.1016\/S0140-6736(08)61206-4","journal-title":"Lancet"},{"issue":"9951","key":"4494_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"K.M. Dungan, S.T. Povedano, T. Forst, J.G.G. Gonz\u00e1lez, C. Atisso, W. Sealls, J.L. Fahrbach, Once-Weekly dulaglutide versus Once-Daily liraglutide in Metformin-Treated patients with type 2 diabetes (AWARD-6): A Randomised, Open-Label, phase 3, Non-Inferiority trial. Lancet. 384(9951), 1349\u20131357 (2014). https:\/\/doi.org\/10.1016\/S0140-6736(14)60976-4","journal-title":"Lancet"},{"issue":"1","key":"4494_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/dc11-0931","volume":"35","author":"J Dushay","year":"2012","unstructured":"J. Dushay, C. Gao, G.S. Gopalakrishnan, M. Crawley, E.K. Mitten, E. Wilker, J. Mullington, E. Maratos-Flier, Short-Term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 35(1), 4\u201311 (2012). https:\/\/doi.org\/10.2337\/dc11-0931","journal-title":"Diabetes Care"},{"issue":"11","key":"4494_CR28","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s13300-023-01462-w","volume":"14","author":"A Esteghamati","year":"2023","unstructured":"A. Esteghamati, M. Zamanzadeh, M. Malek, M. Khaledi, A. Monavari, L. Najafi, Z. Banazadeh et al., Efficacy and safety of a biosimilar liraglutide (Melitide\u00ae) versus the reference liraglutide (Victoza\u00ae) in people with type 2 diabetes mellitus: A Randomized, Double-Blind, noninferiority clinical trial. Diabetes Therapy. 14(11), 1889\u20131902 (2023). https:\/\/doi.org\/10.1007\/s13300-023-01462-w","journal-title":"Diabetes Therapy"},{"issue":"3","key":"4494_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"A. Faurschou, M. Gyldenl\u00f8ve, U. Rohde, J.P. Thyssen, C. Zachariae, L. Skov, F.K. Knop, T. Vilsb\u00f8ll, Lack of effect of the Glucagon-like Peptide-1 receptor agonist liraglutide on psoriasis in Glucose-Tolerant Patients - A randomized Placebo-Controlled trial. J. Eur. Acad. Dermatol. Venereol. 29(3), 555\u2013559 (2015). https:\/\/doi.org\/10.1111\/jdv.12629","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"4494_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2337\/dc18-1760","volume":"42","author":"M Fayfman","year":"2019","unstructured":"M. Fayfman, R.J. Galindo, D.J. Rubin, D.L. Mize, I. Anzola, M.A. Urrutia, C. Ramos et al., A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 42(3), 450\u2013456 (2019). https:\/\/doi.org\/10.2337\/dc18-1760","journal-title":"Diabetes Care"},{"issue":"8","key":"4494_CR31","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1007\/s12325-023-02536-8","volume":"40","author":"P Feng","year":"2023","unstructured":"P. Feng, X. Sheng, Y. Ji, S. Urva, F. Wang, S. Miller, C. Qian, Z. An, Y. Cui, A phase 1 multiple dose study of Tirzepatide in Chinese patients with type 2 diabetes. Adv. Therapy. 40(8), 3434\u20133445 (2023). https:\/\/doi.org\/10.1007\/s12325-023-02536-8","journal-title":"Adv. Therapy"},{"issue":"4","key":"4494_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"K.C. Ferdinand, W.B. White, D.A. Calhoun, E.M. Lonn, P.T. Sager, R. Brunelle, H.H. Jiang, R.J. Threlkeld, K.E. Robertson, M.J. Geiger, Effects of the Once-Weekly Glucagon-like Peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 64(4), 731\u2013737 (2014). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03062","journal-title":"Hypertension"},{"issue":"9","key":"4494_CR33","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"A. Flint, G. Andersen, P. Hockings, L. Johansson, A. Morsing, M. Sundby Palle, T. Vogl, R. Loomba, L. Plum-M\u00f6rschel, Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with Non-Alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 54(9), 1150\u20131161 (2021). https:\/\/doi.org\/10.1111\/apt.16608","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"9","key":"4494_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Fr\u00edas","year":"2021","unstructured":"J.P. Fr\u00edas, P. Auerbach, H.S. Bajaj, Y. Fukushima, I. Lingvay, S. Macura, A.L. S\u00f8ndergaard, T.I. Tankova, N. Tentolouris, J.B. Buse, Efficacy and safety of Once-Weekly semaglutide 2\u00b70 Mg versus 1\u00b70 Mg in patients with type 2 diabetes (SUSTAIN FORTE): A Double-Blind, Randomised, phase 3B trial. Lancet Diabetes Endocrinol. 9(9), 563\u2013574 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00174-1","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"4494_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"J.P. Frias, E. Bonora, L.N. Ruiz, Y.G. Li, Z. Yu, Z. Milicevic, R. Malik, M.A. Bethel, D.A. Cox, Efficacy and safety of dulaglutide 3.0 Mg and 4.5 Mg versus dulaglutide 1.5 Mg in Metformin-Treated patients with type 2 diabetes in a randomized controlled trial (Award-11). Diabetes Care. 44(3), 765\u2013773 (2021). https:\/\/doi.org\/10.2337\/dc20-1473","journal-title":"Diabetes Care"},{"issue":"12","key":"4494_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"J.P. Fr\u00edas, C. Guja, E. Hardy, A. Ahmed, F. Dong, P. \u00d6hman, S.A. Jabbour, Exenatide once weekly plus Dapagliflozin once daily versus exenatide or Dapagliflozin alone in patients with type 2 diabetes inadequately controlled with Metformin monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, phase 3, randomised control. Lancet Diabetes Endocrinol. 4(12), 1004\u20131016 (2016). https:\/\/doi.org\/10.1016\/S2213-8587(16)30267-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"4494_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"J.P. Frias, M.A. Nauck, J. Van, C. Benson, R. Bray, X. Cui, Z. Milicevic, S. Urva, A. Haupt, D.A. Robins, Efficacy and tolerability of Tirzepatide, a dual Glucose-Dependent insulinotropic peptide and Glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-Week, Randomized, double-Blind, Placebo-Controlled study to evaluate different do. Diabetes Obes. Metabolism. 22(6), 938\u2013946 (2020). https:\/\/doi.org\/10.1111\/dom.13979","journal-title":"Diabetes Obes. Metabolism"},{"issue":"3","key":"4494_CR38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, D. Skovgaard, The effect of semaglutide 2.4 Mg once weekly on energy Intake, Appetite, control of Eating, and gastric emptying in adults with obesity. Diabetes Obes. Metabolism. 23(3), 754\u2013762 (2021). https:\/\/doi.org\/10.1111\/dom.14280","journal-title":"Diabetes Obes. Metabolism"},{"issue":"4","key":"4494_CR39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","volume":"13","author":"A Garber","year":"2011","unstructured":"A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, B. Bode, Liraglutide, a Once-Daily human Glucagon-like peptide 1 Analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metabolism. 13(4), 348\u2013356 (2011). https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01356.x","journal-title":"Diabetes Obes. Metabolism"},{"issue":"10","key":"4494_CR40","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"W.T. Garvey, R.L. Batterham, M. Bhatta, S. Buscemi, L.N. Christensen, J.P. Frias, E. J\u00f3dar et al., Two-Year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28(10), 2083\u20132091 (2022). https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat. Med."},{"issue":"2","key":"4494_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.14255","volume":"23","author":"C Gibbons","year":"2021","unstructured":"C. Gibbons, J. Blundell, S. Tetens Hoff, K. Dahl, R. Bauer, T. B\u00e6kdal, Effects of oral semaglutide on energy Intake, food Preference, Appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes. Metabolism. 23(2), 581\u2013588 (2021). https:\/\/doi.org\/10.1111\/dom.14255","journal-title":"Diabetes Obes. Metabolism"},{"issue":"12","key":"4494_CR42","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"F. Giorgino, M. Benroubi, J.-H. Sun, A.G. Zimmermann, V. Pechtner, Efficacy and safety of Once- weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on Metformin and glimepiride (AWARD-2). Diabetes Care. 38(12), 2241\u20132249 (2015). https:\/\/doi.org\/10.2337\/dc14-1625","journal-title":"Diabetes Care"},{"issue":"10","key":"4494_CR43","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1464-5491.2012.03745.x","volume":"29","author":"G Grunberger","year":"2012","unstructured":"G. Grunberger, A. Chang, G. Garcia Soria, F.T. Botros, R. Bsharat, Z. Milicevic, Monotherapy with the Once-Weekly GLP-1 analogue dulaglutide for 12weeks in patients with Type2 diabetes: Dose-Dependent effects on glycaemic control in a Randomized, Double-Blind, Placebo-Controlled study. Diabet. Med. 29(10), 1260\u20131267 (2012). https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03745.x","journal-title":"Diabet. Med."},{"issue":"12","key":"4494_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S2468-1253(17)30285-6","volume":"2","author":"H Halawi","year":"2017","unstructured":"H. Halawi, D. Khemani, D. Eckert, J. O\u2019Neill, H. Kadouh, K. Grothe, M.M. Clark et al., Effects of liraglutide on Weight, Satiation, and gastric functions in obesity: A Randomised, Placebo-Controlled pilot trial. Lancet Gastroenterol. Hepatol. 2(12), 842\u2013843 (2017). https:\/\/doi.org\/10.1016\/S2468-1253(17)30285-6","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"4494_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"M. Husain, A.L. Birkenfeld, M. Donsmark, K. Dungan, F.G. Eliaschewitz, D.R. Franco, O.K. Jeppesen et al., Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381(9), 841\u2013851 (2019). https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"4494_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2337\/dc15-1025","volume":"39","author":"T Idorn","year":"2016","unstructured":"T. Idorn, F.K. Knop, M.B. J\u00f8rgensen, T. Jensen, M. Resuli, P.M. Hansen, K.B. Christensen, J.J. Holst, M. Hornum, B. Feldt-Rasmussen, Safety and efficacy of liraglutide in patients with type 2 diabetes and End-Stage renal disease: an Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, randomized trial. Diabetes Care. 39(2), 206\u2013213 (2016). https:\/\/doi.org\/10.2337\/dc15-1025","journal-title":"Diabetes Care"},{"issue":"6","key":"4494_CR47","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdi.14000","volume":"14","author":"T Iijima","year":"2023","unstructured":"T. Iijima, M. Shibuya, Y. Ito, Y. Terauchi, Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. J. Diabetes Invest. 14(6), 774\u2013781 (2023). https:\/\/doi.org\/10.1111\/jdi.14000","journal-title":"J. Diabetes Invest."},{"issue":"3","key":"4494_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"A.M. Jastreboff, L.J. Aronne, N.N. Ahmad, S. Wharton, L. Connery, B. Alves, A. Kiyosue et al., Tirzepatide once weekly for the treatment of obesity. N Engl. J. Med. 387(3), 205\u2013216 (2022). https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl. J. Med."},{"issue":"1","key":"4494_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.2040-1124.2012.00238.x","volume":"4","author":"L Ji","year":"2013","unstructured":"L. Ji, Y. Onishi, C.W. Ahn, P. Agarwal, C.-W. Chou, H. Haber, K. Guerrettaz, M.K. Boardman, Efficacy and safety of exenatide Once-Weekly vs exenatide Twice-Daily in Asian patients with type 2 diabetes mellitus. J. Diabetes Invest. 4(1), 53\u201361 (2013). https:\/\/doi.org\/10.1111\/j.2040-1124.2012.00238.x","journal-title":"J. Diabetes Invest."},{"issue":"12","key":"4494_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/0091270010389468","volume":"51","author":"J Jiang","year":"2011","unstructured":"J. Jiang, J. Zhang, L.V. Jacobsen, The Pharmacokinetics, Pharmacodynamics, and tolerability of Liraglutide, a Once-Daily human GLP-1 Analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J. Clin. Pharmacol. 51(12), 1620\u20131627 (2011). https:\/\/doi.org\/10.1177\/0091270010389468","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"4494_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","volume":"8","author":"NJ Johansen","year":"2020","unstructured":"N.J. Johansen, T.F. Dejgaard, A. Lund, C. Schl\u00fcntz, C.S. Frandsen, J.L. Forman, N.J. Wewer Albrechtsen et al., Efficacy and safety of Meal-Time administration of Short-Acting exenatide for glycaemic control in type 1 diabetes (MAG1C): A Randomised, Double-Blind, Placebo-Controlled trial. Lancet Diabetes Endocrinol. 8(4), 313\u2013324 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30030-9","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"4494_CR52","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1507\/endocrj.EJ17-0189","volume":"64","author":"S Kaneko","year":"2017","unstructured":"S. Kaneko, T. Oura, A. Matsui, T. Shingaki, Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 Mg compared with insulin glargine in patients with type 2 diabetes. Endocr. J. 64(12), 1165\u20131172 (2017). https:\/\/doi.org\/10.1507\/endocrj.EJ17-0189","journal-title":"Endocr. J."},{"issue":"5","key":"4494_CR53","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"DM Kendall","year":"2005","unstructured":"D.M. Kendall, M.C. Riddle, J. Rosenstock, D. Zhuang, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with Metformin and a sulfonylurea. Diabetes Care. 28(5), 1083\u20131091 (2005). https:\/\/doi.org\/10.2337\/diacare.28.5.1083","journal-title":"Diabetes Care"},{"issue":"6","key":"4494_CR54","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/dc06-2375","volume":"30","author":"D Kim","year":"2007","unstructured":"D. Kim, L. MacConell, D. Zhuang, P.A. Kothare, M. Trautmann, M. Fineman, K. Taylor, Effects of Once-Weekly dosing of a Long-Acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 30(6), 1487\u20131493 (2007). https:\/\/doi.org\/10.2337\/dc06-2375","journal-title":"Diabetes Care"},{"key":"4494_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"MK Klausen","year":"2022","unstructured":"M.K. Klausen, M.E. Jensen, M. M\u00f8ller, N. Le Dous, A.-M.\u00d8. Jensen, V.A. Zeeman, C.-F. Johannsen et al., Exenatide once weekly for alcohol use disorder investigated in a Randomized, Placebo-Controlled clinical trial. JCI Insight. 7, 19 (2022). https:\/\/doi.org\/10.1172\/jci.insight.159863","journal-title":"JCI Insight"},{"issue":"10","key":"4494_CR56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1089\/dia.2013.0366","volume":"16","author":"DJ Klein","year":"2014","unstructured":"D.J. Klein, T. Battelino, D.J. Chatterjee, L.V. Jacobsen, P.M. Hale, S. Arslanian, J. De Schepper et al., Liraglutide\u2019s Safety, Tolerability, Pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A Randomized, Double-Blind, Placebo-Controlled trial. Diabetes Technol. Ther. 16(10), 679\u2013687 (2014). https:\/\/doi.org\/10.1089\/dia.2013.0366","journal-title":"Diabetes Technol. Ther."},{"issue":"11","key":"4494_CR57","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1111\/dom.13422","volume":"20","author":"S Korsatko","year":"2018","unstructured":"S. Korsatko, L. Jensen, M. Brunner, S. Sach-Friedl, M.D. Tarp, A.G. Holst, S.R. Heller, T.R. Pieber, Effect of Once-Weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A Randomized, Placebo-Controlled, Double-Blind, crossover trial. Diabetes Obes. Metabolism. 20(11), 2565\u20132573 (2018). https:\/\/doi.org\/10.1111\/dom.13422","journal-title":"Diabetes Obes. Metabolism"},{"issue":"7","key":"4494_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"J.R. Larsen, L. Vedtofte, M.S.L. Jakobsen, H.R. Jespersen, M.I. Jakobsen, C.K. Svensson, K. Koyuncu et al., Effect of liraglutide treatment on prediabetes and overweight or obesity in Clozapine- or Olanzapine-Treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry. 74(7), 719\u2013728 (2017). https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"issue":"10077","key":"4494_CR59","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Le Roux","year":"2017","unstructured":"Le C.W. Roux, A. Astrup, K. Fujioka, F. Greenway, D.C.W. Lau, L. Van Gaal, R.V. Ortiz et al., 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A Randomised, Double-Blind trial. Lancet. 389(10077), 1399\u20131409 (2017). https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7","journal-title":"Lancet"},{"issue":"5","key":"4494_CR60","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","volume":"38","author":"MEJ Lean","year":"2014","unstructured":"M.E.J. Lean, R. Carraro, N. Finer, H. Hartvig, M.L. Lindegaard, S. R\u00f6ssner, L. Van Gaal, A. Astrup, Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in Obese, Non-Diabetic adults. Int. J. Obes. 38(5), 689\u2013697 (2014). https:\/\/doi.org\/10.1038\/ijo.2013.149","journal-title":"Int. J. Obes."},{"key":"4494_CR61","doi-asserted-by":"publisher","unstructured":"M. Lind, I.B. Hirsch, J. Tuomilehto, S. Dahlqvist, B. Ahr\u00e9n, O. Torffvit, S. Attvall et al., Liraglutide in People Treated for Type 2 Diabetes with Multiple Daily Insulin Injections: Randomised Clinical Trial (MDI Liraglutide Trial). BMJ (Online) 351, no. (Lind M., lind.marcus@telia.com; Attvall S.) Institute of Medicine, University of Gothenburg, Gothenburg, Sweden(Lind M., marcus@telia.com; Dahlqvist S.) Department of Medicine, Uddevalla Hospital, NU Hospital Group, Uddevalla, Sweden(Hirsch I.B.) Un (2015). https:\/\/doi.org\/10.1136\/bmj.h5364","DOI":"10.1136\/bmj.h5364"},{"issue":"9","key":"4494_CR62","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","volume":"41","author":"I Lingvay","year":"2018","unstructured":"I. Lingvay, C.V. Desouza, K.S. Lalic, L. Rose, T. Hansen, J. Zacho, T.R. Pieber, A 26-Week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without Metformin. Diabetes Care. 41(9), 1926\u20131937 (2018). https:\/\/doi.org\/10.2337\/dc17-2381","journal-title":"Diabetes Care"},{"issue":"6","key":"4494_CR63","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"R. Loomba, M.F. Abdelmalek, M.J. Armstrong, M. Jara, M.S. Kj\u00e6r, N. Krarup, E. Lawitz et al., Semaglutide 2\u00b74 Mg once weekly in patients with Non-Alcoholic Steatohepatitis-Related cirrhosis: A Randomised, Placebo-Controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8(6), 511\u2013522 (2023). https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"19","key":"4494_CR64","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. J\u00f3dar, L.A. Leiter, I. Lingvay et al., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl. J. Med. 375(19), 1834\u20131844 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4494_CR65","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"C. Mathieu, B. Zinman, J.U. Hemmingsson, V. Woo, P. Colman, E. Christiansen, M. Linder, B. Bode, Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one Treat-to-Target randomized trial. Diabetes Care. 39(10), 1702\u20131710 (2016). https:\/\/doi.org\/10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"issue":"10","key":"4494_CR66","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.12534","volume":"17","author":"J. Miyagawa","year":"2015","unstructured":"J. Miyagawa, M. Odawara, T. Takamura, N. Iwamoto, Y. Takita, T. Imaoka, Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Dulaglutide Is Non-Inferior to Once-Daily Liraglutide and Superior to Placebo in Japanese Patients with Type 2 Diabetes: A 26-Week Randomized Phase III Study. Diabetes. Obes. Metabolism. 17(10), 974\u2013983 (2015) https:\/\/doi.org\/10.1111\/dom.12534","journal-title":"Obes. Metabolism"},{"issue":"10","key":"4494_CR67","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","volume":"158","author":"J Mok","year":"2023","unstructured":"J. Mok, M.O. Adeleke, A. Brown, C.G. Magee, C. Firman, C. Makahamadze, F.C. Jassil et al., Safety and efficacy of Liraglutide, 3.0 Mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 158(10), 1003\u20131011 (2023). https:\/\/doi.org\/10.1001\/jamasurg.2023.2930","journal-title":"JAMA Surg."},{"issue":"8","key":"4494_CR68","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","volume":"30","author":"TJ Moretto","year":"2008","unstructured":"T.J. Moretto, D.R. Milton, T.D. Ridge, L.A. Macconell, T. Okerson, A.M. Wolka, R.G. Brodows, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic Drug-Naive patients with type 2 diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study. Clin. Ther. 30(8), 1448\u20131460 (2008). https:\/\/doi.org\/10.1016\/j.clinthera.2008.08.006","journal-title":"Clin. Ther."},{"issue":"8","key":"4494_CR69","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","volume":"37","author":"M Nauck","year":"2014","unstructured":"M. Nauck, R.S. Weinstock, G.E. Umpierrez, B. Guerci, Z. Skrivanek, Z. Milicevic, Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 37(8), 2149\u20132158 (2014). https:\/\/doi.org\/10.2337\/dc13-2761","journal-title":"Diabetes Care"},{"issue":"9","key":"4494_CR70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","volume":"9","author":"IJ Neeland","year":"2021","unstructured":"I.J. Neeland, S.P. Marso, C.R. Ayers, B. Lewis, R. Oslica, W. Francis, S. Rodder, A. Pandey, P.H. Joshi, Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A Randomised, Double-Blind, Placebo-Controlled, clinical trial. Lancet Diabetes Endocrinol. 9(9), 595\u2013605 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00179-0","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4494_CR71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","volume":"35","author":"M Nylander","year":"2017","unstructured":"M. Nylander, S. Fr\u00f8ssing, H.V. Clausen, C. Kistorp, J. Faber, S.O. Skouby, Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial. Reprod. Biomed. Online. 35(1), 121\u2013127 (2017). https:\/\/doi.org\/10.1016\/j.rbmo.2017.03.023","journal-title":"Reprod. Biomed. Online"},{"issue":"3","key":"4494_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/dom.12602","volume":"18","author":"M Odawara","year":"2016","unstructured":"M. Odawara, J. Miyagawa, N. Iwamoto, Y. Takita, T. Imaoka, T. Takamura, Once-Weekly Glucagon-like Peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with Once-Daily liraglutide in Japanese patients with type 2 diabetes: 52weeks of treatment in a randomized phase III study. Diabetes Obes. Metabolism. 18(3), 249\u2013257 (2016). https:\/\/doi.org\/10.1111\/dom.12602","journal-title":"Diabetes Obes. Metabolism"},{"issue":"10148","key":"4494_CR73","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"P.M. O\u2019Neil, A.L. Birkenfeld, B. McGowan, O. Mosenzon, S.D. Pedersen, S. Wharton, C.G. Carson, C.H. Jepsen, M. Kabisch, J.P.H. Wilding, Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A Randomised, Double-Blind, placebo and active Controlled, Dose-Ranging, phase 2 trial. Lancet. 392(10148), 637\u2013649 (2018). https:\/\/doi.org\/10.1016\/S0140-6736(18)31773-2","journal-title":"Lancet"},{"key":"4494_CR74","doi-asserted-by":"publisher","unstructured":"D. Papamargaritis, W. Al-Najim, J.Z.M. Lim, J. Crane, D.H. Bodicoat, S. Barber, M. Lean et al., Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 Mg in weight management services (STRIVE Study): A Multicentre, Open-Label, Parallel-Group, randomized controlled trial. Lancet Reg. Health - Europe. 39 (2024). https:\/\/doi.org\/10.1016\/j.lanepe.2024.100853","DOI":"10.1016\/j.lanepe.2024.100853"},{"key":"4494_CR75","doi-asserted-by":"publisher","unstructured":"F.J. Pasquel, M.A. Urrutia, S. Cardona, K.W.Z. Coronado, B. Albury, M.C. Perez-Guzman, R.J. Galindo et al., Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide versus Insulin Glargine for the Management of Patients with Type 2 Diabetes after Hospital Discharge. Diabetes, Obesity and Metabolism 23, no. 6 (2021): 1351\u201360. https:\/\/doi.org\/10.1111\/dom.14347","DOI":"10.1111\/dom.14347"},{"issue":"7","key":"4494_CR76","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"T.R. Pieber, B. Bode, A. Mertens, Y.M. Cho, E. Christiansen, C.L. Hertz, S.O.R. Wallenstein et al., Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): A Multicentre, Open-Label, Randomised, phase 3a trial. Lancet Diabetes Endocrinol. 7(7), 528\u2013539 (2019). https:\/\/doi.org\/10.1016\/S2213-8587(19)30194-9","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4494_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"X. Pi-Sunyer, A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, D.C.W. Lau et al., A Randomized, controlled trial of 3.0 Mg of liraglutide in weight management. N. Engl. J. Med. 373(1), 11\u201322 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"4494_CR78","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/anae.14180","volume":"73","author":"JAW Polderman","year":"2018","unstructured":"J.A.W. Polderman, S.C.J. van Steen, B. Thiel, M.B. Godfried, P.L. Houweling, M.W. Hollmann, J.H. DeVries, B. Preckel, J. Hermanides, Peri-Operative management of patients with Type-2 diabetes mellitus undergoing Non-Cardiac surgery using Liraglutide, Glucose\u2013Insulin\u2013Potassium infusion or intravenous insulin bolus regimens: A randomised controlled trial. Anaesthesia. 73(3), 332\u2013339 (2018). https:\/\/doi.org\/10.1111\/anae.14180","journal-title":"Anaesthesia"},{"issue":"10192","key":"4494_CR79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"R. Pratley, A. Amod, S.T. Hoff, T. Kadowaki, I. Lingvay, M. Nauck, K.B. Pedersen, T. Saugstrup, J.J. Meier, Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): A Randomised, Double-Blind, phase 3a trial. Lancet. 394(10192), 39\u201350 (2019). https:\/\/doi.org\/10.1016\/S0140-6736(19)31271-1","journal-title":"Lancet"},{"issue":"4","key":"4494_CR80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"R.E. Pratley, V.R. Aroda, I. Lingvay, J. L\u00fcdemann, C. Andreassen, A. Navarria, A. Viljoen, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A Randomised, Open-Label, phase 3b trial. Lancet Diabetes Endocrinol. 6(4), 275\u2013286 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9724","key":"4494_CR81","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","volume":"375","author":"RE Pratley","year":"2010","unstructured":"R.E. Pratley, M. Nauck, T. Bailey, E. Montanya, R. Cuddihy, S. Filetti, A.B. Thomsen, R.E. S\u00f8ndergaard, M. Davies, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-Week, Randomised, Parallel-Group, Open-Label trial. Lancet. 375(9724), 1447\u20131456 (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)60307-8","journal-title":"Lancet"},{"issue":"12","key":"4494_CR82","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"H.W. Rodbard, J. Rosenstock, L.H. Canani, C. Deerochanawong, J. Gumprecht, S.\u00d8. Lindberg, I. Lingvay, A.L. S\u00f8ndergaard, M.B. Treppendahl, E. Montanya, Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 42(12), 2272\u20132281 (2019). https:\/\/doi.org\/10.2337\/dc19-0883","journal-title":"Diabetes Care"},{"key":"4494_CR83","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","volume":"220","author":"ST Roos","year":"2016","unstructured":"S.T. Roos, L. Timmers, P.S. Biesbroek, R. Nijveldt, O. Kamp, A.C. van Rossum, G.P.J. van Hout et al., No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. Int. J. Cardiol. 220, 809\u2013814 (2016). https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.283","journal-title":"Int. J. Cardiol."},{"issue":"10295","key":"4494_CR84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"J. Rosenstock, C. Wysham, J.P. Fr\u00edas, S. Kaneko, C.J. Lee, L. Fern\u00e1ndez Land\u00f3, H. Mao, X. Cui, C.A. Karanikas, V.T. Thieu, Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes (SURPASS-1): A Double-Blind, Randomised, phase 3 trial. Lancet. 398(10295), 143\u2013155 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"14","key":"4494_CR85","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"D. Rubino, N. Abrahamsson, M. Davies, D. Hesse, F.L. Greenway, C. Jensen, I. Lingvay et al., Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14), 1414\u20131425 (2021). https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"JAMA"},{"issue":"2","key":"4494_CR86","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"D.M. Rubino, F.L. Greenway, U. Khalid, P.M. O\u2019Neil, J. Rosenstock, R. S\u00f8rrig, T.A. Wadden, A. Wizert, W.T. Garvey, Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327(2), 138\u2013150 (2022). https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"2","key":"4494_CR87","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"D Russell-Jones","year":"2012","unstructured":"D. Russell-Jones, R.M. Cuddihy, M. Hanefeld, A. Kumar, J.G. Gonz\u00e1lez, M. Chan, A.M. Wolka, M.K. Boardman, Efficacy and safety of exenatide once weekly versus Metformin, Pioglitazone, and sitagliptin used as monotherapy in Drug-Naive patients with type 2 diabetes (DURATION-4): A 26-Week Double-Blind study. Diabetes Care. 35(2), 252\u2013258 (2012). https:\/\/doi.org\/10.2337\/dc11-1107","journal-title":"Diabetes Care"},{"issue":"5","key":"4494_CR88","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.clinthera.2008.05.004","volume":"30","author":"SL Schwartz","year":"2008","unstructured":"S.L. Schwartz, R.E. Ratner, D.D. Kim, Y. Qu, L.L. Fechner, S.M. Lenox, J.H. Holcombe, Effect of exenatide on 24-Hour blood glucose profile compared with placebo in patients with type 2 diabetes: A Randomized, Double-Blind, Two-Arm, Parallel-Group, placebo-Controlled, 2-Week study. Clin. Ther. 30(5), 858\u2013867 (2008). https:\/\/doi.org\/10.1016\/j.clinthera.2008.05.004","journal-title":"Clin. Ther."},{"issue":"2","key":"4494_CR89","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Y. Seino, Y. Terauchi, T. Osonoi, D. Yabe, N. Abe, T. Nishida, J. Zacho, S. Kaneko, Safety and efficacy of semaglutide once weekly vs sitagliptin once Daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes. Metabolism. 20(2), 378\u2013388 (2018). https:\/\/doi.org\/10.1111\/dom.13082","journal-title":"Diabetes Obes. Metabolism"},{"issue":"2","key":"4494_CR90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-0031-1295484","volume":"62","author":"S Shi","year":"2012","unstructured":"S. Shi, Y. Liu, Z. Li, J. Wu, X. Zhou, F. Zeng, Pharmacokinetics, Pharmacodynamics, and tolerability of a generic formulation of exenatide: A Randomized, Open-Label, Single- and Multiple-Dose study in healthy Chinese volunteers. Arzneimittel-Forschung\/Drug Res. 62(2), 75\u201382 (2012). https:\/\/doi.org\/10.1055\/s-0031-1295484","journal-title":"Arzneimittel-Forschung\/Drug Res."},{"issue":"4","key":"4494_CR91","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"C. Sorli, S.-I. Harashima, G.M. Tsoukas, J. Unger, J.D. Karsb\u00f8l, T. Hansen, S.C. Bain, Efficacy and safety of Once-Weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A Double-Blind, Randomised, placebo-Controlled, Parallel-Group, Multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 5(4), 251\u2013260 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"4494_CR92","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1507\/endocrj.EJ14-0147","volume":"61","author":"Y Terauchi","year":"2014","unstructured":"Y. Terauchi, Y. Satoi, M. Takeuchi, T. Imaoka, Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: Dose-Dependent effects on glycaemic control in a Randomised, Double-Blind, Placebo-Controlled study. Endocr. J. 61(10), 949\u2013959 (2014). https:\/\/doi.org\/10.1507\/endocrj.EJ14-0147","journal-title":"Endocr. J."},{"issue":"8","key":"4494_CR93","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"K.R. Tuttle, M.C. Lakshmanan, B. Rayner, R.S. Busch, A.G. Zimmermann, D.B. Woodward, F.T. Botros, Dulaglutide versus insulin glargine in patients with type 2 diabetes and Moderate-to-Severe chronic kidney disease (AWARD-7): A Multicentre, Open-Label, randomised trial. Lancet Diabetes Endocrinol. 6(8), 605\u2013617 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"4494_CR94","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"G. Umpierrez, S.T. Povedano, F.P. Manghi, L. Shurzinske, V. Pechtner, Efficacy and safety of dulaglutide monotherapy versus Metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 37(8), 2168\u20132176 (2014). https:\/\/doi.org\/10.2337\/dc13-2759","journal-title":"Diabetes Care"},{"issue":"9","key":"4494_CR95","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1210\/jc.2019-00087","volume":"104","author":"LA Van Meijel","year":"2019","unstructured":"Van L.A. Meijel, H.M. Rooijackers, C.J. Tack, B.E. De Galan, Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes: A randomized controlled trial. J. Clin. Endocrinol. Metab. 104(9), 4143\u20134150 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00087","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4494_CR96","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"T.A. Wadden, A.M. Chao, S. Machineni, R. Kushner, J. Ard, G. Srivastava, B. Halpern et al., Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat. Med. 29(11), 2909\u20132918 (2023). https:\/\/doi.org\/10.1038\/s41591-023-02597-w","journal-title":"Nat. Med."},{"issue":"11","key":"4494_CR97","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"T.A. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo, P.M. Hale, L. Aronne, Weight maintenance and additional weight loss with liraglutide after Low-Calorie-Diet-Induced weight loss: the SCALE maintenance randomized study. Int. J. Obes. 37(11), 1443\u20131451 (2013). https:\/\/doi.org\/10.1038\/ijo.2013.120","journal-title":"Int. J. Obes."},{"key":"4494_CR98","doi-asserted-by":"publisher","unstructured":"W. Wang, L. Nev\u00e1rez, E. Filippova, K.H. Song, B. Tao, L. Gu, F. Wang, P. Li, J. Yang, Efficacy and Safety of Once-Weekly Dulaglutide versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and\/or a Sulphonylurea: A 52-Week Open-Label, Randomized Phase III Trial. Diabetes, Obesity and Metabolism 21, no. 2 (2019): 234\u201343. https:\/\/doi.org\/10.1111\/dom.13506","DOI":"10.1111\/dom.13506"},{"issue":"6","key":"4494_CR99","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/2050640620925968","volume":"8","author":"A-ML Wegeberg","year":"2020","unstructured":"A.-M.L. Wegeberg, C.S. Hansen, A.D. Farmer, J.S. Karmisholt, A.M. Drewes, P.E. Jakobsen, B. Brock, C. Brock, Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A Randomised, Double-Blind, Placebo-Controlled trial. United Eur. Gastroenterol. J. 8(6), 695\u2013704 (2020). https:\/\/doi.org\/10.1177\/2050640620925968","journal-title":"United Eur. Gastroenterol. J."},{"issue":"9","key":"4494_CR100","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"R.S. Weinstock, B. Guerci, G. Umpierrez, M.A. Nauck, Z. Skrivanek, Z. Milicevic, Safety and efficacy of Once-Weekly dulaglutide versus sitagliptin after 2years in Metformin-Treated patients with type 2 diabetes (AWARD-5): A Randomized, phase III study. Diabetes Obes. Metabolism. 17(9), 849\u2013858 (2015). https:\/\/doi.org\/10.1111\/dom.12479","journal-title":"Diabetes Obes. Metabolism"},{"issue":"11","key":"4494_CR101","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, Van L.F. Gaal, I. Lingvay, B.M. McGowan et al., Once-Weekly semaglutide in adults with overweight or obesity. N Engl. J. Med. 384(11), 989\u20131002 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4494_CR102","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2337\/dc16-0238","volume":"39","author":"CH Wysham","year":"2016","unstructured":"C.H. Wysham, L. MacConell, E. Hardy, Efficacy and safety of multiple doses of exenatide Once-Monthly suspension in patients with type 2 diabetes: A phase II randomized clinical trial. Diabetes Care. 39(10), 1768\u20131776 (2016). https:\/\/doi.org\/10.2337\/dc16-0238","journal-title":"Diabetes Care"},{"key":"4494_CR103","doi-asserted-by":"publisher","unstructured":"C.H. Wysham, L.A. Macconell, D.G. Maggs, M. Zhou, P.S. Griffin, M.E. Trautmann, Five-Year Efficacy and Safety Data of Exenatide Once Weekly: Long-Term Results from the DURATION-1 Randomized Clinical Trial. Mayo Clinic Proceedings 90, no. 3 (2015): 356\u201365. https:\/\/doi.org\/10.1016\/j.mayocp.2015.01.008","DOI":"10.1016\/j.mayocp.2015.01.008"},{"issue":"1","key":"4494_CR104","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/dom.13056","volume":"20","author":"CH Wysham","year":"2018","unstructured":"C.H. Wysham, J. Rosenstock, M.L. Vetter, F. Dong, P. \u00d6hman, N. Iqbal, Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes. Metabolism. 20(1), 165\u2013172 (2018). https:\/\/doi.org\/10.1111\/dom.13056","journal-title":"Diabetes Obes. Metabolism"},{"issue":"5","key":"4494_CR105","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"D. Yabe, J. Nakamura, H. Kaneto, S. Deenadayalan, A. Navarria, M. Gislum, N. Inagaki, Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an Open-Label, Randomised, Active-Controlled, phase 3a trial. Lancet Diabetes Endocrinol. 8(5), 392\u2013406 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30074-7","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"4494_CR106","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Y. Yamada, H. Katagiri, Y. Hamamoto, S. Deenadayalan, A. Navarria, K. Nishijima, Dose-Response, Efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): A 52-Week, phase 2\/3a, Randomised, controlled trial. Lancet Diabetes Endocrinol. 8(5), 377\u2013391 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30075-9","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4494_CR107","doi-asserted-by":"publisher","unstructured":"L. Zhao, Z. Cheng, Y. Lu, M. Liu, H. Chen, M. Zhang, R. Wang, Y. Yuan, X. Li, Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA, no. (Zhao L.; Li X., li.xiaoying@zs-hospital.sh.cn) Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China(Cheng Z.) Department of Endocrinology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, China (2024). https:\/\/doi.org\/10.1001\/jama.2024.9217","DOI":"10.1001\/jama.2024.9217"},{"key":"4494_CR108","doi-asserted-by":"publisher","first-page":"1509947","DOI":"10.3389\/fmed.2025.1509947","volume":"12","author":"X Huang","year":"2025","unstructured":"X. Huang, M. Wu, B. Huang, Y. Zhang, Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Front. Med. (Lausanne). 12, 1509947 (2025). https:\/\/doi.org\/10.3389\/fmed.2025.1509947","journal-title":"Front. Med. (Lausanne)"},{"key":"4494_CR109","doi-asserted-by":"publisher","unstructured":"A. Ismaiel, G.G.M. Scarlata, I. Boitos et al., Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int J. Obes. (Lond) Published Online 2025:1\u201312. https:\/\/doi.org\/10.1038\/s41366-025-01859-6","DOI":"10.1038\/s41366-025-01859-6"},{"key":"4494_CR110","doi-asserted-by":"publisher","unstructured":"X. Xie, S. Yang, S. Deng, Y. Liu, Z. Xu, B. He, Comparative Gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a bayesian network meta-analysis. Front. Pharmacol. 16(1613610) (2025). https:\/\/doi.org\/10.3389\/fphar.2025.1613610","DOI":"10.3389\/fphar.2025.1613610"},{"key":"4494_CR111","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"H. Yao, A. Zhang, D. Li et al., Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 384, e076410 (2024). https:\/\/doi.org\/10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"issue":"1","key":"4494_CR112","doi-asserted-by":"publisher","first-page":"e000773","DOI":"10.1136\/bmjdrc-2019-000773","volume":"8","author":"CH Wysham","year":"2020","unstructured":"C.H. Wysham, J. Rosenstock, M.L. Vetter, H. Wang, E. Hardy, N. Iqbal, Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. BMJ Open. Diabetes Res. Care. 8(1), e000773 (2020). https:\/\/doi.org\/10.1136\/bmjdrc-2019-000773","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"4494_CR113","doi-asserted-by":"publisher","unstructured":"M. Pinto, L. Brennan, K. Diehl, S. Lin, S. Heacock, Real-world comparison of oral versus injectable semaglutide for the reduction of hemoglobin A1C and weight in patients with type 2 diabetes. J Pharm. Technol Published Online 2024:87551225241289959. https:\/\/doi.org\/10.1177\/87551225241289959","DOI":"10.1177\/87551225241289959"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04494-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:45:01Z","timestamp":1767617101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04494-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4494"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04494-3","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study did not involve the use of human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study did not involve the use of human subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"23"}}